Home LiteratureArticle Details
PMID: 10734296 Published · ppublish English Case Reports Journal Article Multicenter Study Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion.

Bone marrow transplantation ·Vol. 25 ·No. 6 ·2000-03-00 ·Pages 623-32

Orsini E, Alyea EP, Schlossman R, Canning C, Soiffer RJ, Chillemi A, Neuberg D, Anderson KC, Ritz J

Abstract

Recent reports of clinical responses following donor lymphocyte infusions (DLI) in patients with relapsed multiple myeloma (MM) after allogeneic BMT have demonstrated the ability of allogeneic cells to mediate a graft-versus-myeloma (GVM) effect, but the mechanisms involved have not been determined. To identify changes in the T cell compartment associated with DLI, we performed a molecular analysis of the T cell receptor (TCR) repertoire in four patients with relapsed MM who received infusions of CD4+ lymphocytes from HLA-identical sibling donors. Three of the four patients demonstrated a clinical anti-myeloma response following DLI but also developed graft-versus-host disease (GVHD). The TCR repertoire was examined after PCR amplification of 24 Vbeta gene subfamilies. This method determines the relative utilization of each Vbeta gene subfamily and also allows the identification of clonal and oligoclonal T cell populations through analysis of CDR3 regions for each TCR Vbeta gene subfamily. Serial blood samples were obtained over at least a 1 year period before and after DLI and results compared to 10 normal donors. Serial analysis of CDR3 size profiles demonstrated the appearance of clonal T cell populations after DLI in each of the three responding patients. The appearance of some clones was noted within the first 3 months after DLI and coincided with decreasing levels of monoclonal paraprotein indicating an ongoing GVM response. Other T cell clones appeared at later time points and coincided with the development of GVHD. These findings demonstrate that T cell clones with different patterns of onset can be identified in the peripheral blood of MM patients following DLI. Further functional characterization of these distinct clonal expansions will be required to determine whether these T cell clones are mediators of either anti-myeloma or anti-host activity.

MeSH Terms
Adult Bone Marrow Transplantation Clone Cells/immunology Complementarity Determining Regions Female Graft vs Host Disease/immunology Graft vs Tumor Effect/immunology Humans Immunoglobulin Variable Region/chemistry,immunology Lymphocyte Transfusion/adverse effects Male Middle Aged Multiple Myeloma/etiology,therapy Receptors, Antigen, T-Cell/genetics,immunology Receptors, Antigen, T-Cell, alpha-beta/immunology T-Lymphocytes/immunology Transplantation, Homologous
Chemicals
Complementarity Determining Regions Immunoglobulin Variable Region Receptors, Antigen, T-Cell Receptors, Antigen, T-Cell, alpha-beta
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Orsini E
Center for Hematologic Oncology, Department of Adult Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Alyea E P
Schlossman R
Canning C
Soiffer R J
Chillemi A
Neuberg D
Anderson K C
Ritz J
Article Info
Journal
Bone marrow transplantation
Abbr.
Bone Marrow Transplant
ISSN
0268-3369
Published
2000-03-00
Pages
623-32
Language
English
Region
England
NLM ID
8702459
Subset
IM
Grants
NIAID NIH HHS · AI29530 · United States
NCI NIH HHS · CA78378 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com